Last reviewed · How we verify
hepcortespenlisimut-L
Hepcortespenlisimut-L is a recombinant human prohepcidin analog that stimulates the production of hepcidin, a hormone that regulates iron metabolism.
Hepcortespenlisimut-L is a recombinant human prohepcidin analog that stimulates the production of hepcidin, a hormone that regulates iron metabolism. Used for Treatment of iron overload in patients with beta-thalassemia major.
At a glance
| Generic name | hepcortespenlisimut-L |
|---|---|
| Also known as | V5 |
| Sponsor | Immunitor LLC |
| Drug class | Iron metabolism regulator |
| Target | Hepcidin |
| Modality | Biologic |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
By increasing hepcidin levels, hepcortespenlisimut-L aims to reduce iron overload in the body, which can be beneficial for patients with conditions such as hemochromatosis. This mechanism is distinct from traditional iron chelation therapies, which remove excess iron from the body. Instead, hepcortespenlisimut-L promotes the body's natural iron regulation processes.
Approved indications
- Treatment of iron overload in patients with beta-thalassemia major
Common side effects
- Injection site reactions
Key clinical trials
- Open Label Trial of Immunotherapy for Advanced Liver Cancer (PHASE2)
- Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hepcortespenlisimut-L CI brief — competitive landscape report
- hepcortespenlisimut-L updates RSS · CI watch RSS
- Immunitor LLC portfolio CI